{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:20:11Z","timestamp":1648988411652},"reference-count":26,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.beha.2013.10.006","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T03:52:14Z","timestamp":1381895534000},"page":"261-268","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are immunoconjugates approaching \u201cstandard of care\u201d in AML?"],"prefix":"10.1016","volume":"26","author":[{"given":"Elihu","family":"Estey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2013.10.006_bib1","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib2","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clml.2012.12.006","article-title":"CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes","volume":"13","author":"Zheng","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.beha.2013.10.006_bib4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3109\/10428194.2012.728596","article-title":"CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis","volume":"54","author":"Fathi","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2013.10.006_bib5","first-page":"199S","article-title":"The promise of targeted {alpha}-particle therapy","volume":"46","author":"Mulford","year":"2005","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.beha.2013.10.006_bib6","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (\u201cmylotarg\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.10.006_bib8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3324\/haematol.11329","article-title":"Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia","volume":"92","author":"Breccia","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2013.10.006_bib9","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2013.10.006_bib10","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood.V99.12.4343","article-title":"Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib11","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"Lowenberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-01-466706","article-title":"A\u00a0phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.10.006_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR Study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2013.10.006_bib16","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.10.006_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2013.10.006_bib19","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2013.10.006_bib20","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0140-6736(12)60534-0","article-title":"Treatment of AML: resurrection for gemtuzumab ozogamicin?","volume":"379","author":"Estey","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.10.006_bib21","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2012.43.0132","article-title":"Gemtuzumab ozogamicin: time to resurrect?","volume":"30","author":"Ravandi","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.10.006_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3589.3589","article-title":"SGN-CD33A: a novel CD33-directed antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical antitumor activity against multi-drug resistant human AML","volume":"120","author":"Sutherland","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.768.768","article-title":"Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML)","volume":"118","author":"Jurcic","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib24","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","article-title":"Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia","volume":"121","author":"Bertoli","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients","volume":"113","author":"Sekeres","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.006_bib26","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","article-title":"Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia","volume":"104","author":"Lo-Coco","year":"2004","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T01:23:16Z","timestamp":1596676996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692613000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1521692613000649"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2013.10.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are immunoconjugates approaching \u201cstandard of care\u201d in AML?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2013.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}